Exicure (XCUR) News Today $4.55 -0.10 (-2.15%) Closing price 04:00 PM EasternExtended Trading$4.61 +0.06 (+1.21%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Exicure (NASDAQ:XCUR) Stock Price Up 4% - What's Next?October 21 at 2:40 AM | americanbankingnews.comExicure announces near-term strategic prioritiesOctober 6, 2025 | msn.comExicure appoints Josephine Cardarelli as president, CSOOctober 6, 2025 | msn.comExicure, Inc.: Exicure Highlights Recent Achievements and Near-term Strategic PrioritiesOctober 6, 2025 | finanznachrichten.deExicure Reports Progress in Burixafor (GPC-100) Phase 2 Trial for Multiple Myeloma and Plans Expansion into Sickle Cell Disease and AML with New Leadership AppointmentsOctober 6, 2025 | quiverquant.comQExicure Highlights Recent Achievements and Near-term Strategic PrioritiesOctober 6, 2025 | globenewswire.comExicure, Inc. Reports Second Quarter 2025 Financial Results | XCUR Stock NewsAugust 8, 2025 | gurufocus.comExicure, Inc. Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsAugust 4, 2025 | businesswire.comStocks to Watch: Exicure, TTECAugust 3, 2025 | marketwatch.comExicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantAugust 1, 2025 | businesswire.comXCUR | Exicure Inc. Annual Cash Flow Statement - MarketWatchJuly 19, 2025 | marketwatch.comIs Exicure Stock (XCUR) Experiencing a Dead Cat Bounce?June 30, 2025 | msn.comExicure Shares Up After Swing to Profit in 1QJune 27, 2025 | marketwatch.comExicure, Inc. Reports First Quarter 2025 Financial ResultsJune 27, 2025 | businesswire.comExicure (NASDAQ:XCUR) Stock Price Down 5.8% - Here's WhyJune 18, 2025 | marketbeat.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comExicure (NASDAQ:XCUR) Trading Down 4.5% - Here's WhyMay 28, 2025 | marketbeat.comExicure, Inc. (NASDAQ:XCUR) Short Interest Down 19.8% in AprilMay 4, 2025 | marketbeat.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short InterestApril 20, 2025 | marketbeat.comCarlyle Group Inc. Acquires 225,308 Shares of Exicure, Inc. (NASDAQ:XCUR)April 16, 2025 | marketbeat.comExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comExicure, Inc. Reports Full Year 2024 Financial ResultsMarch 18, 2025 | gurufocus.comExicure secures Australian patent for cancer treatmentMarch 15, 2025 | investing.comExicure announces issuance of new patent in AustraliaMarch 15, 2025 | markets.businessinsider.comExicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in AustraliaMarch 13, 2025 | gurufocus.comKuehn Law Encourages Investors of Exicure, Inc. to Contact Law FirmJanuary 27, 2025 | markets.businessinsider.comExicure announces purchase agreement with GPCR TherapeuticsJanuary 24, 2025 | markets.businessinsider.comCORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 22, 2025 | businesswire.comExicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 22, 2025 | businesswire.comExicure signs MOU with GPCR TherapeuticsDecember 27, 2024 | markets.businessinsider.comExicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in BiotechDecember 26, 2024 | businesswire.comExicure, Inc. Announces Shareholders Approve the $8. ...December 21, 2024 | gurufocus.comCORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8. ...December 21, 2024 | gurufocus.comCORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board ChangesDecember 21, 2024 | businesswire.comExicure Names Andy Yoo as President, CEODecember 20, 2024 | marketwatch.comExicure Shareholders Approve Major HiTron Equity FinancingDecember 20, 2024 | tipranks.comExicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board ChangesDecember 20, 2024 | businesswire.comExicure Inc trading resumesDecember 5, 2024 | markets.businessinsider.comExicure Inc trading halted, volatility trading pauseDecember 5, 2024 | markets.businessinsider.comShort Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 47.9%November 28, 2024 | marketbeat.comHow Is The Market Feeling About Exicure?November 26, 2024 | benzinga.comExicure Signs Equity-Financing Deals With HiTron SystemsNovember 14, 2024 | marketwatch.comXCUR/USD - Curate US DollarOctober 28, 2024 | investing.com(PNGJL.BO)September 19, 2024 | finance.yahoo.com Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XCUR Media Mentions By Week XCUR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XCUR News Sentiment▼0.000.50▲Average Medical News Sentiment XCUR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XCUR Articles This Week▼11▲XCUR Articles Average Week Get the Latest News and Ratings for XCUR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Exicure and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cognition Therapeutics News Ovid Therapeutics News VistaGen Therapeutics News Context Therapeutics News Oncolytics Biotech News Inhibikase Therapeutics News Opus Genetics News TScan Therapeutics News Virios Therapeutics News Coya Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XCUR) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredBitcoin is dead?Bitcoin’s historic run may be ending — and Weiss Ratings’ Juan Villaverde, who’s nailed every major crypto bul...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
